Cargando…
MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate ta...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022406/ https://www.ncbi.nlm.nih.gov/pubmed/36938552 http://dx.doi.org/10.20471/acc.2022.61.s3.9 |
_version_ | 1784908724559675392 |
---|---|
author | Murgić, Jure Gregov, Marin Mrčela, Iva Budanec, Mirjana Krengli, Marco Fröbe, Ana Franco, Pierfrancesco |
author_facet | Murgić, Jure Gregov, Marin Mrčela, Iva Budanec, Mirjana Krengli, Marco Fröbe, Ana Franco, Pierfrancesco |
author_sort | Murgić, Jure |
collection | PubMed |
description | Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate target dose deposition while sparing surrounding healthy tissue. Conventional radiotherapy is based on computerized tomography (CT) images both for radiotherapy planning and image-guidance, however, shortcomings of CT as soft tissue imaging tool are well known. Nowadays, our ability to further escalate radiotherapy dose using hypofractionation is limited by uncertainties in CT-based image guidance and verification. Magnetic resonance imaging (MRI) is a well established imaging method for pelvic organs. In prostate cancer specifically, MRI accurately depicts prostate zonal anatomy, rectum, bladder, and pelvic floor structures with previously unseen precision owing to its sharp soft tissue contrast. The advantages of including MRI in the clinical workflow of prostate cancer radiotherapy are multifold. MRI allows for true adaptive radiotherapy to unfold based on daily MRI images taken before, during and after each radiotherapy fraction. It enables accurate dose escalation to the prostate and intraprostatic tumor lesions. Technically, MRI high-strength magnetic field and linear accelerator high energy electromagnetic beams are hardly compatible, and important efforts were made to overcome these technical challenges and integrate MRI and linear accelerator into one single treatment device, called MRI-linac. Different systems are produced by two leading vendors in the field and currently, there are around 100 MRI-linacs worldwide in clinical operations. In this narrative review paper, we discuss historical perspective of image guidance in radiotherapy, basic elements of MRI, current clinical developments in MRI-guided prostate cancer radiotherapy, and challenges associated with the use of MRI-linac in clinical practice. |
format | Online Article Text |
id | pubmed-10022406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb |
record_format | MEDLINE/PubMed |
spelling | pubmed-100224062023-03-18 MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM Murgić, Jure Gregov, Marin Mrčela, Iva Budanec, Mirjana Krengli, Marco Fröbe, Ana Franco, Pierfrancesco Acta Clin Croat Professional Papers Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate target dose deposition while sparing surrounding healthy tissue. Conventional radiotherapy is based on computerized tomography (CT) images both for radiotherapy planning and image-guidance, however, shortcomings of CT as soft tissue imaging tool are well known. Nowadays, our ability to further escalate radiotherapy dose using hypofractionation is limited by uncertainties in CT-based image guidance and verification. Magnetic resonance imaging (MRI) is a well established imaging method for pelvic organs. In prostate cancer specifically, MRI accurately depicts prostate zonal anatomy, rectum, bladder, and pelvic floor structures with previously unseen precision owing to its sharp soft tissue contrast. The advantages of including MRI in the clinical workflow of prostate cancer radiotherapy are multifold. MRI allows for true adaptive radiotherapy to unfold based on daily MRI images taken before, during and after each radiotherapy fraction. It enables accurate dose escalation to the prostate and intraprostatic tumor lesions. Technically, MRI high-strength magnetic field and linear accelerator high energy electromagnetic beams are hardly compatible, and important efforts were made to overcome these technical challenges and integrate MRI and linear accelerator into one single treatment device, called MRI-linac. Different systems are produced by two leading vendors in the field and currently, there are around 100 MRI-linacs worldwide in clinical operations. In this narrative review paper, we discuss historical perspective of image guidance in radiotherapy, basic elements of MRI, current clinical developments in MRI-guided prostate cancer radiotherapy, and challenges associated with the use of MRI-linac in clinical practice. Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2022-10 /pmc/articles/PMC10022406/ /pubmed/36938552 http://dx.doi.org/10.20471/acc.2022.61.s3.9 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. |
spellingShingle | Professional Papers Murgić, Jure Gregov, Marin Mrčela, Iva Budanec, Mirjana Krengli, Marco Fröbe, Ana Franco, Pierfrancesco MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM |
title | MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM |
title_full | MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM |
title_fullStr | MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM |
title_full_unstemmed | MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM |
title_short | MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM |
title_sort | mri-guided radiotherapy for prostate cancer: a new paradigm |
topic | Professional Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022406/ https://www.ncbi.nlm.nih.gov/pubmed/36938552 http://dx.doi.org/10.20471/acc.2022.61.s3.9 |
work_keys_str_mv | AT murgicjure mriguidedradiotherapyforprostatecanceranewparadigm AT gregovmarin mriguidedradiotherapyforprostatecanceranewparadigm AT mrcelaiva mriguidedradiotherapyforprostatecanceranewparadigm AT budanecmirjana mriguidedradiotherapyforprostatecanceranewparadigm AT krenglimarco mriguidedradiotherapyforprostatecanceranewparadigm AT frobeana mriguidedradiotherapyforprostatecanceranewparadigm AT francopierfrancesco mriguidedradiotherapyforprostatecanceranewparadigm |